Ticker Hub
PCRX — AI Analysis & Sentiment
7 recent AI-generated analyses for PCRX. Sentiment and confidence insights updated continuously.
Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees
ISS's recommendation for Pacira's director nominees strengthens management's position in the proxy fight, endorsing the current growth strategy. Th...
Jun 1, 2026Leading Independent Proxy Advisory Firm Glass Lewis Recommends Stockholders Vote “FOR” All of Pacira’s Director Nominees
Glass Lewis's recommendation for Pacira's director nominees signals strong support for current management's 5x30 strategy, reducing uncertainty fro...
May 28, 2026Pacira BioSciences Reports Real-World Study Showing EXPAREL® Use Was Associated with Reduced Opioid Use and Healthcare Costs in Patients Undergoing Total Shoulder Arthroplasty
Pacira BioSciences' latest real-world data strengthens the case for EXPAREL by demonstrating reduced opioid use and costs in shoulder surgery. This...
May 27, 2026DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualified, Independent Board Candidates
Activist investor DOMA Perpetual is launching a proxy fight to replace Pacira BioSciences' management and explore a strategic sale, targeting years...
May 13, 2026Pacira BioSciences Mails Letter to Stockholders
Pacira BioSciences reported solid Q1 2026 financial results, including revenue growth across products and a $50 million share repurchase, indicatin...
May 5, 2026DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.
DOMA Perpetual's board nominations and call for a company sale could catalyze a significant re-rating for Pacira BioSciences. The activist believes...
Mar 11, 2026Pacira BioSciences Reports Fourth Quarter and Full-Year 2025 Financial Results
Pacira BioSciences reported full-year 2025 revenue growth, but its Q4 and full-year profitability metrics declined, which could challenge its expen...
Feb 26, 2026